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SAMHD1 restricts HIV-1 replication in myeloid and
quiescent CD4+ T cells. Here, we show that SAMHD1
restriction activity is regulated by phosphorylation.
SAMHD1 interacts with cyclin A2/cdk1 only in cycling
cells. Cyclin A2/CDK1 phosphorylates SAMHD1 at
the Threonine 592 residue both in vitro and in vivo.
Phosphorylation of SAMHD1 Thr592 correlates with
loss of its ability to restrict HIV-1. Indeed, while
PMA treatment of proliferating THP1 cells results in
reduced Thr592 phosphorylation, activation of
resting peripheral blood mononuclear cells (PBMCs)
and purified quiescent CD4+ T cells results in
increased phosphorylation of SAMHD1 Thr592. Inter-
estingly, we found that treatment of cells by type 1
interferon reduced Thr592 phosphorylation, reinforc-
ing the link between the phosphorylation of SAMHD1
and its antiviral activity. Unlike wild-type SAMHD1,
a phosphorylation-defective mutant was able to
restrict HIV-1 replication in both PMA-treated
and untreated cells. Our results uncover the phos-
phorylation of SAMHD1 at Thr592 by cyclin A2/
CDK1 as a key regulatory mechanism of its antiviral
activity.INTRODUCTION
Among the numerous blocks that oppose the replication of HIV-1
in human cells are restriction factors. Four restriction factors
have been identified to date: (1) Tripartite Motif (TRIM) 5 alpha
(TRIM5a); (2) apolipoprotein B mRNA-editing, enzyme-catalytic,
polypeptide-like 3G (APOBEC3G, A3G); (3) BST-2/Tetherin; and
(4) Sterile Alpha Motif (SAM) domain and HD domain-containing
protein 1 (SAMHD1). These cellular factors mediate a cell-
intrinsic resistance that arrest the viral life cycle at a specific
step (Hrecka et al., 2011; Kirchhoff, 2010; Laguette et al.,
2011; Malim and Bieniasz, 2012).
Indeed, SAMHD1 has been identified as the cellular protein
responsible of the reverse transcription block to HIV-1 infection
observed in myeloid cells as well as in quiescent CD4+ T cells
(Hrecka et al., 2011; Laguette and Benkirane, 2012; Baldauf1036 Cell Reports 3, 1036–1043, April 25, 2013 ª2013 The Authorset al., 2012; Descours et al., 2012). SAMHD1 is constituted of a
sterile alpha motif (SAM) and a HD domain, the presence of
which suggests a putative phosphohydrolase activity (Aravind
and Koonin, 1998) that has been subsequently demonstrated
in vitro (Goldstone et al., 2011; Powell et al., 2011). Indeed,
SAMHD1 possesses a deoxyguanosine-triphosphate (dGTP)-
dependent triphosphate triphosphohydrolase activity, which
hydrolyses the deoxynucleoside triphosphates (dNTPs) to deox-
ynucleoside and inorganic triphosphate. It has thus been
proposed that SAMHD1 limits HIV-1 infection by depleting the
intracellular pool of dNTPs to a level below the one required to
complete the reverse transcription step (Lahouassa et al.,
2012; St Gelais et al., 2012). Nucleic-acid binding and process-
ing in vitro by SAMHD1 has also been reported (Goncalves et al.,
2012; Beloglazova et al., 2013; Tungler et al., 2013), there-
fore suggesting additional SAMHD1-associated restriction
mechanisms.
Unlike TRIM5a, A3G, and BST-2, whose sole expression is
sufficient to block infection by HIV-1, SAMHD1 restriction activ-
ity appears to be subjected to additional regulationmechanisms.
In fact, SAMHD1 was primarily identified in differentiated
myeloid cells, such as monocyte derived dendritic cells
(MDDCs), macrophages, or PMA (phorbol-12myristate-13ace-
tate)-treated THP1 as being responsible for their poor infectabil-
ity by HIV-1 (Berger et al., 2012; Hrecka et al., 2011; Laguette
et al., 2011). However SAMHD1 is expressed in various cell types
where no block to HIV-1 infection has been witnessed. Indeed,
while SAMHD1 is expressed at similar levels in primary resting
and activated CD4+ T cells (Baldauf et al., 2012; Descours
et al., 2012), the latter is fully permissive to HIV-1, suggesting
that additional partners are required for SAMHD1 to be fully
potent against HIV-1, that would either directly regulate the
activity of SAMHD1 or act as cofactors.
Here, we questioned the molecular mechanism underlying the
regulation of SAMHD1 activity. We show that SAMHD1 associ-
ates with the cyclin A2/CDK1 complex that mediates its phos-
phorylation at threonine 592. We further demonstrate that this
phosphorylation event is dependent on the cell proliferation sta-
tus and is a key regulatory mechanism that inhibits the ability of
SAMHD1 to block HIV-1 infection. Finally, we show that unlike
previously described restriction factors that are upregulated
(Harris et al., 2012), SAMHD1 Thr592 phosphorylation is reduced
after type 1 interferon (IFN) treatment, while its expression level
remains insensitive, uncovering a regulation of restriction factors
by IFN.
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Figure 1. SAMHD1 Interacts with Cyclin A2/CDK1 in Proliferating Cells
(A) Sole expression of SAMHD1 is not sufficient to restrict HIV-1 infection. U937 andU937eSAMHD1 cells weremock- or PMA-treated prior infection with 50 ng of
HIV-LUC-G. Luciferase activity was measured at 24 hr p.i. and normalized for protein concentration. The results are expressed relative to infection of mock-
treated U937 cell, which was set to 1.
(B) Tandem affinity purification of SAMHD1 and its cellular partners. Nuclear extracts prepared from THP1 and THP1eSAMHD1 which were mock- or
PMA-treated were subjected to tandem immunoaffinity purification using anti-Flag and subsequently anti-HA antibodies. Immunoprecipitates were separated on
SDS-PAGE. SAMHD1 and its partners were visualized by silver staining.
(C) SAMHD1 interacts with cyclin A2/CDK1 in proliferating cells. Whole-cell extracts (WCEs) were prepared from mock- or PMA-treated THP1 and
THP1eSAMHD1 cells and subjected to immunoprecipitation using anti-Flag antibody. The presence of CDK1, cyclinA2 and SAMHD1was determined bywestern
blot using specific antibodies.RESULTS
SAMHD1 Interacts with Cyclin A2/CDK1 in Proliferating
Cells
To assess for correlation between SAMHD1 expression and its
antiviral activity, we generated U937 cells stably expressing
Flag- and HA-tagged SAMHD1 (U937eSAMHD1). U937 cells
and U937eSAMHD1 were mock- or PMA-treated, and we
measured their susceptibility to infection by HIV-1-containing
luciferase as a reporter gene in place of nef and pseudotyped
with the fusogenic envelope G of the vesicular stomatitis virus
(HIV1-LUC-G). Proliferating U937 and U937eSAMHD1 were
equally permissive to HIV1-LUC-G. Interestingly, when treated
with PMA, expression of SAMHD1 rendered U937 cells 8-fold
less permissive to HIV1-LUC-G than their parental counterpart,
indicating that SAMHD1 restricts HIV-1 infection only in PMA-
treated cells (Figure 1A, upper panel). Western blot analysis of
whole-cell extracts showed that SAMHD1 was equally
expressed in PMA-treated and untreated U937eSAMHD1 cells
(Figure 1A, lower panel). These results strongly suggest that
the sole expression of SAMHD1 is not sufficient to confer resis-
tance to HIV-1 infection. SAMHD1 restriction activity might
require posttranslational modifications or the presence of part-
ner expressed in PMA-treated cells. To test these hypotheses,
we immunopurified SAMHD1 and its interacting partners from
mock- or PMA-treated THP1 cells expressing Flag- and
HA-tagged SAMHD1 (THP1eSAMHD1) (Figure 1B). Proteins
that specifically associate with SAMHD1 were identified by
mass spectrometry. Interestingly, among the interacting part-
ners identified, cyclin A2 and CDK1 were present only whenCSAMHD1 was purified from proliferating THP1 cells (data not
shown). To confirm the interaction between SAMHD1 and cyclin
A2/CDK1 in proliferating cells, eSAMHD1 was immunoprecipi-
tated from THP1eSAMHD1, which were mock- or PMA-treated.
Mock- and PMA-treated THP1 cells were used as controls.
The presence of cyclin A2 and CDK1 in the immunoprecipitates
was assessed by western blot using specific antibodies. As
shown in Figure 1C, cyclin A2 and CDK1 were recovered only
when eSAMHD1was immunoprecipitated from PMA-untreated
THP1eSAMHD1 (Figure 1C, compare lane 2 to lane 1). Loss of
the interaction between SAMHD1 and cyclin A2/CDK1 in PMA-
treated cells is likely due to the loss of cyclin A2 expression as
a result of cell-cycle arrest induced by PMA. Taken together,
these experiments show that SAMHD1 interacts with the cell-
cycle regulator cyclin A2/CDK1. This interaction is dependent
on cellular proliferation and cyclin A2 expression.
SAMHD1 Is Substrate for Cyclin A2/CDK1
The identification of the cell-cycle regulator cyclin A2/CDK1 as
SAMHD1 partner in proliferating cells suggests that SAMHD1
might be a substrate for CDK1. First, we assessed whether
SAMHD1 is modified by phosphorylation. Whole-cell extracts
of proliferating and PMA-treated THP1eSAMHD1were prepared
and separated using the Phos-tag acrylamide technology, which
provides a phosphate affinity SDS-PAGE for mobility shift detec-
tion of phosphorylated proteins (Kinoshita et al., 2006, 2009).
Western blot analysis using SAMHD1-specific antibody revealed
multiple phosphorylated forms of SAMHD1 (Figure 2A). Interest-
ingly, PMA treatment of the cells results in reduction of the
intensity of phosphorylated forms (Figure 2A compare lane 2 toell Reports 3, 1036–1043, April 25, 2013 ª2013 The Authors 1037
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Figure 2. SAMHD1 T592 Is Phosphorylated by Cyclin A2/CDK1
(A) SAMHD1 is phosphorylated in proliferating THP1.Whole-cell extracts (WCE) frommock- or PMA-treated THP1were separated on a 6%Phos-Tag acrylamide
gel and analyzed by western blot using anti-SAMHD1 antibody (left panel). WCE were prepared from THP1eSAMHD1 in absence (PPI) or in presence (+PPI) of
phosphatase inhibitor. Extracts were treatedwith 0U (), 200 U (+), or 400 U (++) of Lambda phosphatase before separation on a 6%Phos-Tag acrylamide or on a
classical 10% acrylamide gels. SAMHD1 was revealed by western blot using anti-SAMHD1 antibody (right panel).
(B) Sequence alignment of the SAMHD1 region containing the threonine 592 residue in vertebrates. The conserved threonine is represented in bold and CDK1
consensus sequence, i.e., (S/T)PX(K/R), is highlighted in gray.
(C) Cyclin A2/CDK1 phosphorylates SAMHD1 in vitro at threonine 592. Left panel: Schematic representation of GST-SAMHD1 constructs (GST is not pictured)
used for in vitro kinase assay. The sterile alpha motif (SAM) and phospho-hydrolase (HD) domains are shown as well as the threonine 592 (Rice et al., 2009).
Middle and right panels: In vitro kinase assays using GST-SAMHD1 recombinant proteins as indicated together with recombinant cyclin A2/CDK1 and 1 mCi
[g-32P] ATP (ATP*). Reactions were separated on SDS-PAGE and visualized by autoradiography (upper panels) or Coomassie stained (lower panels).
(D) Samples corresponding to the in vitro kinase assay shown in (C) (right panel) were separated on SDS-PAGE and immunoprobedwith phospho-specific Thr592
antibody (upper panel) and anti-SAMHD1 antibody (lower panel).
(legend continued on next page)
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lane 1). To confirm that the high-molecular-weight bands corre-
spond to phosphorylated forms of SAMHD1, whole-cell extracts
from proliferating THP1eSAMHD1 cells were mock- or lambda-
phosphatase-treated and separated on Phos-tag acrylamide
gel. Immunodetection of SAMHD1 revealed that phosphatase
treatment leads to reduction of slow migration bands and accu-
mulation of fast-migrating bands. Furthermore, when cell ex-
tracts were prepared in the presence of phosphatase inhibitors,
the intensity of SAMHD1 phosphorylated forms was enhanced
(Figure 2A, compare 4 to lane 1). None of the treatments affected
the expression levels of SAMHD1 (Figure 2A, lower panel). Taken
together, these experiments show that SAMHD1 is modified by
phosphorylation. Alignment of SAMHD1 amino acid sequence
from different species revealed that the threonine 592 (T592) is
well conserved in many vertebrate species including human,
mouse, and rat, and the surrounding sequence matches the
consensus target site (S/TPxK/R) of CDK1 (Figure 2B). Thus,
we first investigated the ability of CDK1 to phosphorylate
SAMHD1 in vitro using wild-type recombinant GST-SAMHD1
or truncation mutants (Figure 2C, left panel) and recombinant
cyclin A2/CDK1 in the presence or absence of [g-32P]ATP. While
cyclin A2/CDK1 was able to phosphorylate wild-type SAMHD1,
SAMHD1 HD domain mutant (HD/AA), and the C-terminal region
(334–626 aa) (Figure 2C, middle panel lanes 5, 6, 10, and 11), no
phosphorylation was observed when C-terminal deletion
mutants were used in the reactions (lanes 7–9). This result dem-
onstrates that in vitro cyclin A2/CDK1 phosphorylates SAMHD1
at the C-terminal domain containing the CDK1 consensus
sequence. To test whether the threonine 592 is the residue
phosphorylated by CDK1, GST-SAMHD1 WT and GST-
SAMHD1T592A (T592 substituted by alanine) were used in
in vitro kinase assay. While CDK1 efficiently phosphorylated
wild-type SAMHD1, it only marginally phosphorylated the
SAMHD1T592A mutant (Figure 2C, right panel, compare lane 5
to lane 6). These results demonstrate that cyclin A2/CDK1 phos-
phorylates SAMHD1 at the T592 in vitro. To further confirm in vivo
SAMHD1 phosphorylation at the T592 residue, we generated
phospho-peptide-specific antibody against the phospho-
peptide sequence surrounding the T592 residue. Specificity of
the phospho-antibody was validated using in vitro phosphoryla-
tion of GST-SAMHD1 by the cyclinA2/CDK1 complex in the
presence of cold ATP. The phospho-specific antibody against
the SAMHD1 phospho-T592 residue detected SAMHD1 protein
in the presence of both the cyclin A2/CDK1 complex and cold
ATP, but could not detect the GST-SAMHD1T592A mutant (Fig-
ure 2D, upper panel). Western blot analysis using anti-SAMHD1
antibody revealed equal amount of both wild-type and T592
SAMHD1 proteins (Figure 2D, lower panel). Next, in vivo detec-
tion of SAMHD1 phosphorylation at the T592 residue was tested
using cell lysates of U937 cells expressing eSAMHD1 or
eSAMHD1T592Amutant. The phospho-specific antibody recog-
nized wild-type SAMHD1 but not the SAMHD1T592A mutant
(data not shown). Both wild-type and SAMHD1T592A mutant(E) SAMHD1 is phosphorylated in vivo on Thr592 residue. Samples (4–6) correspo
PAGE and immunoprobed with phospho-specific Thr592 antibody and with ERK
(F) CDK1 phosphorylates SAMHD1 Thr592 in vivo. U937eSAMHD1 were mock
chloride) for 12 or 24 hr. Cell extracts were prepared and separated on SDS-PAG
Cshow similar nuclear localization (data not shown). Endogenous
SAMHD1 proteins were also recognized by the phospho-
specific antibody, whereas phosphatase-treated proteins
were not (Figure 2E, compare lanes 2 and 3 to lane 1). Further-
more, treatment of U937eSAMHD1 cells with selective CDK1
inhibitor (CGP-74514A hydrochloride, HC) reduced SAMHD1
phosphorylation at T592 residue as witnessed by western blot
using anti-phosphoT592 antibody (Figure 2F). Taken together,
these data show that the generated antibody is specific for
the phosphorylated T592 residue of SAMHD1 and that this res-
idue is a target phosphorylation site of the cyclin A2/CDK1
complex.
SAMHD1 Phosphorylation at T592 Is Regulated upon
T Cell Activation and Interferon Treatment and Is a
Negative Regulator of Its Antiviral Activity
The antiviral activity of SAMHD1 has been observed only in
differentiated noncycling cells such as dendritic cells, macro-
phages, monocytes, and quiescent CD4+ T cells. Indeed,
despite a similar level of SAMHD1 expression in THP1 cells, its
restriction of HIV-1 replication is witnessed only when the cells
are differentiated through PMA treatment (Goujon et al., 2008).
Similarly, resting and activated CD4+ T cells express equal
amount of SAMHD1, while the restriction of HIV-1 is observed
only in the former. Data presented in Figure 2A show that
SAMHD1 phosphorylation is reduced upon PMA treatment of
THP1 cells. Taken together, these results suggest that SAMHD1
phosphorylation inhibits its antiviral activity. We first asked
whether Vpx-mediated degradation of SAMHD1 is affected by
Thr592 phosphorylation. Figure 3A (left panel) shows that Vpx
induces degradation of both unphosphorylated and phosphory-
lated forms of SAMHD1. To assess whether SAMHD1 phosphor-
ylation at T592 residue inversely correlates with its antiviral
activity, THP1 cells were mock- or PMA-treated. The levels of
SAMHD1 and its T592 phosphorylated form were determined
by western blot. Figure 3A (right panel) shows that PMA treat-
ment of THP1 cells results in loss of SAMHD1 phosphorylation
at T592 without affecting the level of SAMHD1. Furthermore,
TCR stimulation of peripheral blood mononuclear cells (PBMCs)
and purified CD4+ T cells obtained from four healthy donors
resulted in dramatic increase of T592phosphorylation (Figure 3B,
upper panels), while SAMHD1 expression level was unchanged
(Figure 3B, lower panels). These results show that T592 phos-
phorylation of SAMHD1 is highly regulated and correlates with
the permissiveness of the cells to HIV-1. In support of this
hypothesis, treatment of THP1 cells with type 1 interferon
resulted in reduced amount of SAMHD1 phosphorylated on
Thr592 residue without affecting the levels of SAMHD1 (Fig-
ure 3C, left panel). Consistently, we observed that IFN treatment
of activated CD4+ T cells, monocyte-derived macrophage
(MDM), and monocyte-derived dendritic cells (MDDCs) also
resulted in reduced amounts of SAMHD1 phosphorylated on
Thr592 residue without affecting the overall levels of SAMHD1nding to experiment shown in the middle panel of (A) were separated on SDS-
1/2 antibody.
-treated (NT) or treated with 1.25 mM of CDK1 inhibitor (CGP-74514A hydro-
E. Western blot analysis was performed using the indicated antibodies.
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Figure 3. SAMDH1 Phosphorylation on Thr592 Residue Is Increased in HIV-1-Permissive Cells and Is Regulated by Type 1 IFN
SAMHD1 is phosphorylated at T592 in HIV-1-permissive THP1, stimulated PBMCs, and CD4+ T lymphocytes.
(A) Western blot analysis of cell extracts from mock- or Vpx-expressing THP1 cells (left panel) and mock- or PMA-treated THP1 (right panel) using the phospho-
specific SAMHD1, anti-HA, and tubulin antibodies as indicated.
(B) PBMCs and purified CD4+ T cells isolated from four healthy donors (D1 to D4) were mock- or TCR-stimulated (CD3/CD28/IL-2). Whole-cell extracts were
separated on SDS-PAGE and analyzed by western blot using the indicated antibodies.
(C) Type 1 IFN treatment downregulates SAMHD1 phosphorylation on Thr592 residue. Left panel: THP1 cells were untreated (NT) or treated with IFN-a
(1,000 U/ml) for 1, 6, and 12 hr. Whole-cell extracts were separated on SDS-PAGE and analyzed by western blot using the indicated antibodies. Right panel:
TCR-activated CD4+ T cells, quiescent CD4+ T cells, monocytes (Mono), macrophages (MDM), and dendritic cells (MDDC) isolated from healthy donor were
treated with type1-IFN (100 U/ml) for 48 hr. Whole-cell extracts were analyzed by western blot using the indicated antibodies.(Figure 3C, right panel). No phosphorylation of Thr592 was
observed in quiescent CD4+ T cells and monocytes, which are
highly refractory to HIV-1 (Figure 3C, right panel). To explore
whether T952 phosphorylation of SAMHD1 inhibits its antiviral
activity, we compared the antiviral activity of wild-type SAMHD1
and the phosphorylation-defective mutant in mock- and PMA-
treated U937 cells. Consistent with results obtained in Figure 1A,
wild-type SAMHD1 restriction activity toward HIV-1 was wit-
nessed only in PMA-treated U937 cells (Figure 4A). Importantly,
SAMHD1 phosphorylation-defective mutant not only restricted
HIV-1 replication in PMA-treated cells, but could also restrict
HIV-1 in untreated U937 cells (Figure 4A). These results show
that phosphorylation of SAMHD1 T592 residue is a negative
regulator of its restriction activity toward HIV-1.1040 Cell Reports 3, 1036–1043, April 25, 2013 ª2013 The AuthorsDISCUSSION
The observation that the sole expression of SAMHD1 in prolifer-
ating cells is not sufficient to confer resistance to HIV-1 led us to
hypothesis that SAMHD1 antiviral activity might be regulated
by posttranslational modification and/or requires a partner
expressed only in the nonproliferating cells where its antiviral
activity is witnessed. Purification of SAMHD1 and its partners
from proliferating and nonproliferating cells led to the recovery
of cyclin A2/CDK1 only in the former. Using in vitro kinase assay
and phospho-specific antibody, we showed that cyclin A2/CDK1
phosphorylates SAMHD1 at the Thr592 residue, which is highly
conserved in vertebrate species and present within a consensus
target site of CDK1. In support for a role of SAMHD1 Thr592 in
AB
Figure 4. Thr592 Phosphorylation of
SAMHD1 Inhibits Its Antiviral Activity
(A) Expression of SAMHD1 phosphorylation-
defective mutant renders U937 cells nonpermis-
sive to HIV-1 infection. U937 cells expressing WT
or SAMHD1 phosphorylation-defective mutant
(1–575) were mock- or PMA-treated and then
infected with 150 ng of HIV1-LUC-G. Luciferase
activity wasmeasured 24 hr p.i. and normalized for
protein concentration. The results are expressed
relative to infection of U937 cells transduced with
empty vector () which was set to 1. Shown are
means ± SD (nR 2).
(B) Model for the regulation of SAMHD1 restriction
activity by phosphorylation at the Thr592 residue.regulating its antiviral activity, we observed that Thr592 was
phosphorylated in HIV-1-permissive cells. Treatment of prolifer-
ating THP1 by PMA, which renders them nonpermissive,
resulted in dramatic reduction of Thr592 phosphorylation. While
Thr592 phosphorylation of SAMHD1 is low in resting CD4+
T cells, which are nonpermissive to HIV-1, TCR activation of
primary CD4+ T cells, which confers high susceptibility to
HIV-1, induced Thr592 phosphorylation. Interestingly, SAMHD1
phosphorylation at Thr592 is also regulated by type 1 interferon.
Indeed, treatment of THP1 cells, activated CD4+ T cells, MDMs
and MDDC by IFN reduced Thr592 phosphorylation without
affecting SAMHD1 levels. This observation is in accordance
with the recent report showing that, unlike the other restriction
factors, SAMHD1 expression is not regulated by IFN in activated
CD4+ T cells and in MDDCs (St Gelais et al., 2012) and extends
this observation to resting CD4+ T cells, monocytes, and MDMs.
Importantly, we show that IFN regulates SAMHD1 antiviral activ-
ity in these primary cells and in THP1 cells by reducing its phos-Cell Reports 3, 1036–104phorylation on Thr592, highlighting
a pathway of regulation of restriction
factors by IFN. It has been reported that
type 1 IFN induces the expression of the
CDK inhibitor p21Waf1/Cip1 (Mandal et al.,
1998; Katayama et al., 2007), whichmight
explain the reduced phosphorylation of
Thr592 residue by CDK1. Alternatively,
IFN might induce a phosphatase activity
responsible for SAMHD1 dephosphoryla-
tion. It will be also important to explore
whether the reduced phosphorylation of
Thr592 residue by IFN might contribute
to the antiviral state induced by IFN in
MDDCs, which is counteracted by Vpx
(Pertel et al., 2011). In conclusion,
Thr592 phosphorylated and nonphos-
phorylated forms of SAMHD1 exist in an
equilibrium, which is in favor of one form
or the other depending on the cells prolif-
eration status and type 1 interferon
treatment (Figure 4B). Finally, unlike
wild-type SAMHD1, the sole expression
of SAMHD1 phosphorylation-defectivemutant is able to confer resistance to HIV-1. Taken together,
our experiments demonstrate that phosphorylation of SAMHD1
at the Thr592 by cyclin A2/CDK1 regulates its restriction activity
toward HIV-1. SAMHD1 is a dGTP-dependent deoxynucleotide
triphosphohydrolase that reduces the cellular pool of dNTPs in
differentiated, noncycling myeloid cells to levels below those
required to support HIV-1 DNA synthesis. Additionally, it has
recently been shown that SAMHD1 is a nucleic acid binding pro-
tein that displays a preference for RNA over DNA (Goncalves
et al., 2012). SAMHD1 also possesses metal-dependent 30 to
50 exonuclease activity against single-stranded DNAs and pref-
erentially cleaves 30 overhangs and RNA in the blunt-ended
RNA/DNA duplexes in vitro. It will be important to determine
whether Thr592 phosphorylation of SAMHD1 might affect its
enzymatic activities. The discovery of SAMHD1 interaction with
and phosphorylation by cyclinA2/CDK1 is not only important
for our understanding of its antiviral activity but will also help
deciphering the cellular function for SAMHD1. Indeed, cyclin3, April 25, 2013 ª2013 The Authors 1041
A2/CDK1 is known to inhibit both DNA replication and histone
mRNA accumulation, marking the end of S phase and entry
into G2 phase. Cyclin A2 is highly expressed during S phase
and degraded for completion of mitosis (Koseoglu et al., 2010).
The fact that SAMHD1 is substrate for this mitotic cyclin sug-
gests that SAMHD1 might also function in regulating cell-cycle
progression.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in Extended Experimental
Procedures.
Cell Lines
Adherent and suspension cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) or in Roswell Park Memorial Institute medium (RPMI-1640)
respectively. Medium were supplemented with 10% of fetal calf serum, antibi-
otics (100 units/ml penicillin G, 100 mg/ml streptomycin), and ultraglutamine
(0.2 mM). All cell-culture reagents were purchased from Lonza. Cell lines
expressing Flag- and HA-tagged proteins were obtained using the previously
described MMLV-based retroviral constructs (Nakatani and Ogryzko, 2003;
Kumar et al., 2009) that contain a selectable marker (puromycin resistance
gene [pOZ-puro]). Puromycin-selected cell lines were grown in appropriate
media supplemented with 1 mg ml1 puromycin. U937 and THP-1 cells were
differentiated overnight with 30 ng ml1 of phorbol 12-myristate 13-acetate
(PMA) (Sigma).
Lambda Phosphatase Treatment
Four millions of nondifferentiated THP-1-SAMHD1-F/H were lysed in
TETN-150 without EDTA containing or not phosphatase inhibitor (PPI cocktail,
Sigma, P2850). Whole-cell extracts (40 mg) were treated with 0, 0.5, or 1 ml of
lambda protein phosphatase (400 U/ml, New England Biolabs, P0753S) for 1 hr
30 at 30C. After adding 10 ml of 63 SDS sample buffer, samples were boiled
for 5 min at 95C.
In Vitro Phosphorylation Assay
Same amount of GST fusion proteins (400 ng) were incubated for 30 min at
30C with recombinant cyclin A2/CDK1 (Sigma) in 20 ml kinase buffer (25 mM
Tris [pH 7.4], 50mMNaCl, 10mMMgCl2, supplemented with 1mMdithiothrei-
tol [DTT] prior to use) including 1 mCi (g-32P) ATP or 1 mM cold ATP. Reactions
were stoppedby the addition of 63 sample buffer and heating for 5min at 95C.
Proteins were separated by SDS-PAGE, followed by autoradiography or
analyzed by western blot with a SAMHD1 antibody and p-SAMHD1 T592.
Infection
After transduction of U937 cells with lentiviral vectors allowing the expression
of SAMHD1-WT ormutants, cells weremock- or PMA-treated for at least 16 hr.
Cells were then infected with doses corresponding to 50 ng or 150 ng of HIV-1
CAp24 with HIV-LUC-G viruses, depending on the experiments. After 24 hr of
infection, infected cells were harvest and viral infection was measured by
quantification of the luciferase activity using the luciferase assay system
according to the manufacturer’s recommendations (Luciferase assay, Prom-
ega) and a Mithras luminometer (Berthold Technologies).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
can be found with this article online at http://dx.doi.org/10.1016/j.celrep.
2013.03.017.
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